Admin or Manager login required
Admin or Manager login required
Admin or Manager login required
Admin or Manager login required
Admin or Manager login required
Admin or Manager login required
Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Structural patterns of the human ABCC4/MRP4 exporter in lipid bilayers rationalize clinically observed polymorphisms

B. Chantemargue, F. Di Meo, K. Berka, N. Picard, H. Arnion, M. Essig, P. Marquet, M. Otyepka, P. Trouillas,

. 2018 ; 133 (-) : 318-327. [pub] 20180310

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19012783

The ABCC4/MRP4 exporter has a clinical impact on membrane transport of a broad range of xenobiotics. It is expressed at key locations for drug disposition or effects such as in the liver, the kidney and blood cells. Several polymorphisms and mutations (e.g., p.Gly187Trp) leading to MRP4 dysfunction are associated with an increased risk of toxicity of some drugs. So far, no human MRP4 structure has been elucidated, precluding rationalization of these dysfunctions at a molecular level. We constructed an atomistic model of the wild type (WT) MRP4 and the p.Gly187Trp mutant embedded in different lipid bilayers and relaxed them for hundreds of nanoseconds by molecular dynamics simulations. The WT MRP4 molecular structure confirmed and ameliorated the general knowledge about the transmembrane helices and the two nucleotide binding domains. Moreover, our model elucidated positions of three generally unresolved domains: L1 (linker between the two halves of the exporter); L0 (N-terminal domain); and the zipper helices (between the two NBDs). Each domain was thoroughly described in view of its function. The p.Gly187Trp mutation induced a huge structural impact on MRP4, mainly affecting NBD 1 structure and flexibility. The structure of transporter enabled rationalization of known dysfunctions associated with polymorphism of MRP4. This model is available to the pharmacology community to decipher the impact of any other clinically observed polymorphism and mutation on drug transport, giving rise to in silico predictive pharmacogenetics.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012783
003      
CZ-PrNML
005      
20190416121621.0
007      
ta
008      
190405s2018 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.phrs.2018.02.029 $2 doi
035    __
$a (PubMed)29530601
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Chantemargue, B $u U1248 INSERM, Univ. Limoges, Fac. Pharmacy, 2 rue du Dr Marcland, 87025, Limoges, France; RCPTM, Department of Physical Chemistry, Fac. Sciences, Palacký University, Olomouc, Czech Republic.
245    10
$a Structural patterns of the human ABCC4/MRP4 exporter in lipid bilayers rationalize clinically observed polymorphisms / $c B. Chantemargue, F. Di Meo, K. Berka, N. Picard, H. Arnion, M. Essig, P. Marquet, M. Otyepka, P. Trouillas,
520    9_
$a The ABCC4/MRP4 exporter has a clinical impact on membrane transport of a broad range of xenobiotics. It is expressed at key locations for drug disposition or effects such as in the liver, the kidney and blood cells. Several polymorphisms and mutations (e.g., p.Gly187Trp) leading to MRP4 dysfunction are associated with an increased risk of toxicity of some drugs. So far, no human MRP4 structure has been elucidated, precluding rationalization of these dysfunctions at a molecular level. We constructed an atomistic model of the wild type (WT) MRP4 and the p.Gly187Trp mutant embedded in different lipid bilayers and relaxed them for hundreds of nanoseconds by molecular dynamics simulations. The WT MRP4 molecular structure confirmed and ameliorated the general knowledge about the transmembrane helices and the two nucleotide binding domains. Moreover, our model elucidated positions of three generally unresolved domains: L1 (linker between the two halves of the exporter); L0 (N-terminal domain); and the zipper helices (between the two NBDs). Each domain was thoroughly described in view of its function. The p.Gly187Trp mutation induced a huge structural impact on MRP4, mainly affecting NBD 1 structure and flexibility. The structure of transporter enabled rationalization of known dysfunctions associated with polymorphism of MRP4. This model is available to the pharmacology community to decipher the impact of any other clinically observed polymorphism and mutation on drug transport, giving rise to in silico predictive pharmacogenetics.
650    _2
$a lipidové dvojvrstvy $x metabolismus $7 D008051
650    12
$a molekulární modely $7 D008958
650    _2
$a proteiny spojené s mnohočetnou rezistencí k lékům $x chemie $x fyziologie $7 D027425
650    _2
$a mutace $7 D009154
650    _2
$a polymorfismus genetický $7 D011110
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Di Meo, F $u U1248 INSERM, Univ. Limoges, Fac. Pharmacy, 2 rue du Dr Marcland, 87025, Limoges, France. Electronic address: florent.di-meo@unilim.fr.
700    1_
$a Berka, K $u RCPTM, Department of Physical Chemistry, Fac. Sciences, Palacký University, Olomouc, Czech Republic.
700    1_
$a Picard, N $u U1248 INSERM, Univ. Limoges, Fac. Pharmacy, 2 rue du Dr Marcland, 87025, Limoges, France; Department of Pharmacology and Toxicology, CHU Limoges, Limoges University Hospital, Limoges Cedex, F-87042, France.
700    1_
$a Arnion, H $u U1248 INSERM, Univ. Limoges, Fac. Pharmacy, 2 rue du Dr Marcland, 87025, Limoges, France.
700    1_
$a Essig, M $u U1248 INSERM, Univ. Limoges, Fac. Pharmacy, 2 rue du Dr Marcland, 87025, Limoges, France.
700    1_
$a Marquet, P $u U1248 INSERM, Univ. Limoges, Fac. Pharmacy, 2 rue du Dr Marcland, 87025, Limoges, France; Department of Pharmacology and Toxicology, CHU Limoges, Limoges University Hospital, Limoges Cedex, F-87042, France.
700    1_
$a Otyepka, M $u RCPTM, Department of Physical Chemistry, Fac. Sciences, Palacký University, Olomouc, Czech Republic.
700    1_
$a Trouillas, P $u U1248 INSERM, Univ. Limoges, Fac. Pharmacy, 2 rue du Dr Marcland, 87025, Limoges, France; RCPTM, Department of Physical Chemistry, Fac. Sciences, Palacký University, Olomouc, Czech Republic.
773    0_
$w MED00005744 $t Pharmacological research $x 1096-1186 $g Roč. 133, č. - (2018), s. 318-327
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29530601 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20190416121647 $b ABA008
999    __
$a ok $b bmc $g 1392093 $s 1051088
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 133 $c - $d 318-327 $e 20180310 $i 1096-1186 $m Pharmacological research $n Pharmacol Res $x MED00005744
LZP    __
$a Pubmed-20190405

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...